Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy?

World Journal of Urology

Volumn 33, Issue 8, 2015, Pages 1079-1085

  Merseburger, Axel S ^a   Hammerer, Peter ^b   Rozet, Francois ^c   Roumeguère, Thierry ^d   Caffo, Orazio ^e   da Silva, Fernando Calais ^f   Alcaraz, Antonio ^g  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Academic Hospital Braunschweig   (Germany)

^c Department of Urology L’Institut Mutualiste Montsouris ^*  (France)

^d ERASME HOSPITAL   (Belgium)

^e SANTA CHIARA HOSPITAL   (Italy)

^f Universidade de Lisboa   (Portugal)

^g UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Backbone androgen deprivation therapy; Castrate resistant prostate cancer; Individualised management

Indexed keywords

ABIRATERONE; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CABAZITAXEL; ENZALUTAMIDE; GONADORELIN; LEUPRORELIN; PHENYLTHIOHYDANTOIN; RADIOISOTOPE; RADIUM; RADIUM CHLORIDE RA 223; SIPULEUCEL T; TAXOID; TISSUE EXTRACT;

AGONISTS; ANALOGS AND DERIVATIVES; HUMAN; MALE; ORCHIECTOMY; PRACTICE GUIDELINE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

ANDROSTENES; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; GONADOTROPIN-RELEASING HORMONE; HUMANS; LEUPROLIDE; MALE; ORCHIECTOMY; PHENYLTHIOHYDANTOIN; PRACTICE GUIDELINES AS TOPIC; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RADIOISOTOPES; RADIUM; TAXOIDS; TISSUE EXTRACTS;

EID: 84938892863     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-014-1406-2     Document Type: Review

References (45)

1. Heidenreich A, Bastian PJ, Bellmunt J et al (2014) EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 65(2):467–479
2. Cookson MS, Roth BJ, Dahm P et al (2013) Castration-resistant prostate cancer: AUA guideline
3. NCCN (2014) NCCN clinical practice guidelines in oncology. Prostate Cancer
4. Fizazi K, Scher HI, Molina A et al (2012) Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13(10):983–992
5. Ryan CJ, Smith MR, de Bono JS et al (2013) Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368(2):138–148
6. Scher HI, Fizazi K, Saad F et al (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367(13):1187–1197
7. Beer TM, Armstrong AJ, Rathkopf DE et al (2014) Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371(5):424–433
8. Kantoff PW, Higano CS, Shore ND et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363(5):411–422
9. Parker C, Nilsson S, Heinrich D et al (2013) Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369(3):213–223
10. de Bono JS, Oudard S, Ozguroglu M et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376(9747):1147–1154
11. Morote J, Orsola A, Planas J et al (2007) Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J Urol 178(4):1290–1295
12. Alcaraz A (2008) Management of the hormone sensitivity of prostate cancer: where are we now? Eur Urol 54(2):247–250
13. Manni A, Bartholomew M, Caplan R et al (1988) Androgen priming and chemotherapy in advanced prostate cancer: evaluation of determinants of clinical outcome. J Clin Oncol 6(9):1456–1466
14. Mostaghel EA, Page ST, Lin DW et al (2007) Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res 67(10):5033–5041
15. Montgomery RB, Mostaghel EA, Vessella R et al (2008) Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 68(11):4447–4454
16. Egan A, Dong Y, Zhang H, Qi Y, Balk SP, Sartor O (2014) Castration-resistant prostate cancer: adaptive responses in the androgen axis. Cancer Treat Rev 40(3):426–433
17. Philips B, Ball C, Sackett D et al (2009) Oxford Centre for evidence-based medicine levels of evidence
18. Attard G, Belldegrun AS, de Bono JS (2005) Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int 96(9):1241–1246
19. Efstathiou E, Titus M, Tsavachidou D et al (2012) Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J Clin Oncol 30(6):637–643
20. Soifer HS, Souleimanian N, Wu S et al (2012) Direct regulation of androgen receptor activity by potent CYP17 inhibitors in prostate cancer cells. J Biol Chem 287(6):3777–3787
21. O’Donnell A, Judson I, Dowsett M et al (2004) Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 90(12):2317–2325
22. Ryan CJ, Peng W, Kheoh T et al (2014) Androgen dynamics and serum PSA in patients treated with abiraterone acetate. Prostate Cancer Prostatic Dis 17(2):192–198
23. Sonpavde G, Attard G, Bellmunt J et al (2011) The role of abiraterone acetate in the management of prostate cancer: a critical analysis of the literature. Eur Urol 60(2):270–278
24. Merseburger AS, Kuczyk MA, Wolff JM (2013) Pathophysiology and therapy of castration-resistant prostate cancer. Der Urologe Ausg A 52(2):219–225
25. Tyrrell CJ, Kaisary AV, Iversen P et al (1998) A randomised comparison of ‘Casodex’ (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 33(5):447–456
26. Wirth MP, See WA, McLeod DG et al (2004) Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. J Urol 172:1865–1870
27. Visakorpi T, Hyytinen E, Koivisto P et al (1995) In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9(4):401–406
28. Bubendorf L, Kononen J, Koivisto P et al (1999) Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res 59(4):803–806
29. Kawata H, Ishikura N, Watanabe M, Nishimoto A, Tsunenari T, Aoki Y (2010) Prolonged treatment with bicalutamide induces androgen receptor overexpression and androgen hypersensitivity. Prostate 70(7):745–754
30. Bohl CE, Gao W, Miller DD, Bell CE, Dalton JT (2005) Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc Natl Acad Sci USA 102(17):6201–6206
31. Belikov S, Oberg C, Jaaskelainen T, Rahkama V, Palvimo JJ, Wrange O (2013) FoxA1 corrupts the antiandrogenic effect of bicalutamide but only weakly attenuates the effect of MDV3100 (Enzalutamide). Mol Cell Endocrinol 365(1):95–107
32. Lee GT, Jung YS, Ha YS, Kim JH, Kim WJ, Kim IY (2013) Bone morphogenetic protein-6 induces castration resistance in prostate cancer cells through tumor infiltrating macrophages. Cancer Sci 104(8):1027–1032
33. Efstathiou E, Titus M, Wen S et al (2014) Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer. Eur Urol. doi:10.1016/j.eururo.2014.05.005
34. Tran C, Ouk S, Clegg NJ et al (2009) Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324(5928):787–790
35. Smith MR, Borre M, Rathenborg P et al (2013) Efficacy and safety of enzalutamide (ENZA) monotherapy in hormone-naive prostate cancer (HNPC). J Clin Oncol 31(15):5001
36. Bong GW, Clarke HS, Hancock WC, Keane TE (2008) Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer. Urology 71(6):1177–1180
37. Shamash J, Davies A, Ansell W et al (2008) A phase II study investigating the re-induction of endocrine sensitivity following chemotherapy in androgen-independent prostate cancer. Br J Cancer 98:22–24
38. Taylor CD, Elson P, Trump DL (1993) Importance of continued testicular suppression in hormone-refractory prostate cancer. J Clin Oncol 11(11):2167–2172
39. Hussain M, Wolf M, Marshall E, Crawford ED, Eisenberger M (1994) Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report. J Clin Oncol 12(9):1868–1875
40. Lee JL, Eun Kim J, Ahn JH et al (2011) Role of androgen deprivation treatment in patients with castration-resistant prostate cancer, receiving docetaxel-based chemotherapy. Am J Clin Oncol 34(2):140–144
41. Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351(15):1502–1512
42. Scher HI, Halabi S, Tannock I et al (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26(7):1148–1159
43. Gravis G, Fizazi K, Joly F et al (2013) Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 14(2):149–158
44. Smith MR, Saad F, Oudard S et al (2013) Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol 31(30):3800–3806
45. Sydes MR, Parmar MK, Mason MD et al (2012) Flexible trial design in practice—stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial. Trials 13:168